Aridis Pharmaceuticals (ARDS) Stock Forecast, Price & News

Aridis Pharmaceuticals (NASDAQ:ARDS) Frequently Asked Questions

Is Aridis Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aridis Pharmaceuticals stock.
View analyst ratings for Aridis Pharmaceuticals or view top-rated stocks.

Are investors shorting Aridis Pharmaceuticals?

Aridis Pharmaceuticals saw a increase in short interest in April. As of April 30th, there was short interest totaling 109,500 shares, an increase of 52.1% from the April 15th total of 72,000 shares. Based on an average daily volume of 324,500 shares, the days-to-cover ratio is presently 0.3 days.
View Aridis Pharmaceuticals' Short Interest.

When is Aridis Pharmaceuticals' next earnings date?

Aridis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Aridis Pharmaceuticals.

How were Aridis Pharmaceuticals' earnings last quarter?

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) posted its quarterly earnings results on Monday, May, 16th. The company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.07.
View Aridis Pharmaceuticals' earnings history.

What price target have analysts set for ARDS?

2 brokerages have issued 1-year price targets for Aridis Pharmaceuticals' shares. Their forecasts range from $10.00 to $19.00. On average, they expect Aridis Pharmaceuticals' share price to reach $14.50 in the next year. This suggests a possible upside of 1,242.6% from the stock's current price.
View analysts' price targets for Aridis Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Aridis Pharmaceuticals' key executives?

Aridis Pharmaceuticals' management team includes the following people:

• Dr. Vu L. Truong Ph.D., Founder, CEO, Chief Scientific Officer & Director (Age 58, Pay $566.12k)
• Dr. Hasan Jafri M.D., Chief Medical Officer
• Mr. Fred Kurland J.D., M.B.A., Chief Financial Officer (Age 71)
• Mr. Jeffrey J. Fessler Esq., J.D., Acting Gen. Counsel (Age 59)

Who are some of Aridis Pharmaceuticals' key competitors?

Some companies that are related to Aridis Pharmaceuticals include Aeglea BioTherapeutics (AGLE), Rain Therapeutics (RAIN), Viracta Therapeutics (VIRX), Annovis Bio (ANVS), HCW Biologics (HCWB), Kazia Therapeutics (KZIA), Xilio Therapeutics (XLO), Enlivex Therapeutics (ENLV), BioVie (BIVI), eFFECTOR Therapeutics (EFTR), BriaCell Therapeutics (BCTX), Mustang Bio (MBIO), Genprex (GNPX), Pyxis Oncology (PYXS) and SCYNEXIS (SCYX).
View all of ARDS's competitors.

What other stocks do shareholders of Aridis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), Pluristem Therapeutics (PSTI) and SCYNEXIS (SCYX).

When did Aridis Pharmaceuticals IPO?

(ARDS) raised $28 million in an IPO on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

What is Aridis Pharmaceuticals' stock symbol?

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

Who are Aridis Pharmaceuticals' major shareholders?

Aridis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Commonwealth Equity Services LLC (3.26%), Vanguard Group Inc. (2.96%), Minot Wealth Management LLC (0.36%), Group One Trading L.P. (0.15%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Aridis Pharmaceuticals stock include John F Hamilton and Vu Truong.
View institutional ownership trends for Aridis Pharmaceuticals.

Which institutional investors are buying Aridis Pharmaceuticals stock?

ARDS stock was bought by a variety of institutional investors in the last quarter, including Commonwealth Equity Services LLC, Minot Wealth Management LLC, Group One Trading L.P., and Vanguard Group Inc.. Company insiders that have bought Aridis Pharmaceuticals stock in the last two years include John F Hamilton, and Vu Truong.
View insider buying and selling activity for Aridis Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Aridis Pharmaceuticals?

Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aridis Pharmaceuticals' stock price today?

One share of ARDS stock can currently be purchased for approximately $1.08.

How much money does Aridis Pharmaceuticals make?

Aridis Pharmaceuticals has a market capitalization of $19.12 million and generates $1.53 million in revenue each year. The company earns $-42.19 million in net income (profit) each year or ($3.790010) on an earnings per share basis.

How many employees does Aridis Pharmaceuticals have?

Aridis Pharmaceuticals employs 33 workers across the globe.

What is Aridis Pharmaceuticals' official website?

The official website for Aridis Pharmaceuticals is www.aridispharma.com.

How can I contact Aridis Pharmaceuticals?

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct, San Jose CA, 95138. The company can be reached via phone at (408) 385-1742, via email at [email protected], or via fax at 408-960-3822.